300347 泰格医药
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入3,250,444-3.21%6,603,1207,384,0397,085,4715,213,538
减:营业总成本2,942,26312.03%5,610,0485,554,1255,156,5443,637,765
    其中:营业成本2,272,46612.21%4,361,1074,535,5114,277,0082,942,883
               财务费用63,282-492.85%38,067(108,324)(158,124)(216,363)
               资产减值损失(4,295)-49.02%1,255(29,725)(2,416)(12,915)
公允价值变动收益(89,644)-8.90%(501,688)352,771535,8571,815,390
投资收益233,001229.36%166,642338,175102,751312,283
    其中:对联营企业和合营企业的投资收益166,386277.33%31,271105,18339,76314,348
营业利润444,258-35.34%664,4192,486,9412,582,3993,696,967
利润总额442,689-35.85%664,4622,488,5332,585,3773,684,566
减:所得税费用79,861-39.73%216,630338,606313,652292,864
净利润362,828-34.93%447,8312,149,9272,271,7253,391,702
减:非控股权益(20,509)-131.68%42,688125,077265,173517,539
股东净利润383,337-22.22%405,1432,024,8502,006,5522,874,163

市场价值指针
每股收益 (元) *0.450-21.05%0.4702.3402.3203.310
每股派息 (元) *----0.3000.5680.5500.500
每股净资产 (元) *23.837-0.71%23.89824.10222.44720.774
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容